These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38873607)

  • 21. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
    Foucher ED; Ghigo C; Chouaib S; Galon J; Iovanna J; Olive D
    Front Immunol; 2018; 9():1044. PubMed ID: 29868007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies.
    Jin Y; Christenson ES; Zheng L; Li K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):945-958. PubMed ID: 38690749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer.
    Mahadevan KK; Dyevoich AM; Chen Y; Li B; Sugimoto H; Sockwell AM; McAndrews KM; Sthanam LK; Wang H; Shalapour S; Watowich SS; Kalluri R
    Science; 2024 Jun; 384(6703):eadh4567. PubMed ID: 38935717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intratumoral CD38
    Zhu H; Xu J; Wang W; Zhang B; Liu J; Liang C; Hua J; Meng Q; Yu X; Shi S
    EBioMedicine; 2024 May; 103():105098. PubMed ID: 38608514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
    Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
    Sahin IH; Askan G; Hu ZI; O'Reilly EM
    Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.
    Bengsch F; Knoblock DM; Liu A; McAllister F; Beatty GL
    Cancer Immunol Immunother; 2017 Dec; 66(12):1609-1617. PubMed ID: 28856392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
    Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
    Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
    Hilmi M; Bartholin L; Neuzillet C
    World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review.
    Li HB; Yang ZH; Guo QQ
    Cell Commun Signal; 2021 Nov; 19(1):117. PubMed ID: 34819086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
    Bazhin AV; von Ahn K; Fritz J; Bunge H; Maier C; Isayev O; Neff F; Siveke JT; Karakhanova S
    Oncoimmunology; 2022; 11(1):2043037. PubMed ID: 35251770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
    Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
    Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
    Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.